None
Conditions
Interventions
Guoup 1:0.3mg/kg Ciprofol+4ug/kg Oliceridine
Guoup 2:0.1mg/kg Ciprofol+4ug/kg Oliceridine
Guoup 3:0.5mg/kg Ciprofol+8ug/kg Oliceridine
Guoup 4:0.1mg/kg Ciprofol+8ug/kg Oliceridine
Guoup 5:0.1mg/kg Ciprofol+0ug/kg Oliceridine
Guoup 6:0.3mg/kg Ciprofol+0ug/kg Oliceridine
Guoup 7:0.5mg/kg Ciprofol+0ug/kg Oliceridine
Guoup 8:0.5mg/kg Ciprofol+4ug/kg Oliceridine
Guoup 9:0.3mg/kg Ciprofol+8ug/kg Oliceridine
Sponsors
The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: Willing to participate in this trial, aged 65 to 80 years, Asa Class I-II, no history of mental illness, no history of drug abuse and alcohol abuse, no history of allergy to Ciprofol, no liver or kidney dysfunction, preoperative blood pressure and blood glucose were well controlled (SBP =160mmHg, DBP =95mmHg, fasting blood glucose =7.0 mmol/L) .
Exclusion criteria
Exclusion criteria: Obese people(BMI>30);The amount of bleeding was more than 1000ml.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastroscopic examination of the body to stimulate the response;Circulatory response;Side effects of circulatory or respiratory inhibition;Recovery time;Incidence of adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| SBP;DBP;HR;SpO2;Whether to add Ciprofol; | — |
Countries
China
Contacts
Public ContactZheng Ying
The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University(Huai'an First People's Hospital)
Outcome results
None listed